Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2011, Article ID 217060, 7 pages
http://dx.doi.org/10.4061/2011/217060
Research Article

A Comparative Analysis of Biomarker Expression and Molecular Subtypes of Pure Ductal Carcinoma In Situ and Invasive Breast Carcinoma by Image Analysis: Relationship of the Subtypes with Histologic Grade, Ki67, p53 Overexpression, and DNA Ploidy

Departments of Pathology and Surgical Oncology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9073, USA

Received 12 April 2011; Accepted 30 June 2011

Academic Editor: Debra A. Tonetti

Copyright © 2011 Venetia R. Sarode et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. L. Tsikitis and M. A. Chung, “Biology of ductal carcinoma in situ classification based on biologic potential,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 29, no. 3, pp. 305–310, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. L. Wiechmann and H. M. Kuerer, “The molecular journey from ductal carcinoma in situ to invasive breast cancer,” Cancer, vol. 112, no. 10, pp. 2130–2142, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. P. Tang, S. I. Hajdu, and G. H. Lyman, “Ductal carcinoma in situ: a review of recent advances,” Current Opinion in Obstetrics and Gynecology, vol. 19, no. 1, pp. 63–67, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. F. Wärnberg, H. Nordgren, L. Bergkvist, and L. Holmberg, “Tumour markers in breast carcinoma correlate with grade rather than with invasiveness,” British Journal of Cancer, vol. 85, no. 6, pp. 869–874, 2001. View at Publisher · View at Google Scholar · View at PubMed
  5. M. Lacroix, R. A. Toillon, and G. Leclercq, “Stable “portrait” of breast tumors during progression: data from biology, pathology and genetics,” Endocrine-Related Cancer, vol. 11, no. 3, pp. 497–522, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Sørlie, C. M. Perou, R. Tibshirani et al., “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10869–10874, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. C. M. Perou, S. S. Jeffrey, M. van de Rijn et al., “Distinctive gene expression patterns in human mammary epithelial cells and breast cancers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 16, pp. 9212–9217, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Bhargava, J. Striebel, S. Beriwal et al., “Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers,” International Journal of Clinical and Experimental Pathology, vol. 2, no. 5, pp. 444–455, 2009. View at Google Scholar · View at Scopus
  9. R. M. Tamimi, H. J. Baer, J. Marotti et al., “Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer,” Breast Cancer Research, vol. 10, no. 4, article no. R67, 2008. View at Publisher · View at Google Scholar · View at PubMed
  10. C. M. Perou, T. Sørile, M. B. Eisen et al., “Molecular portraits of human breast tumours,” Nature, vol. 406, no. 6797, pp. 747–752, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. C. U. Cheang, S. K. Chia, D. Voduc et al., “Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer,” Journal of the National Cancer Institute, vol. 101, no. 10, pp. 736–750, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. C. A. Livasy, C. M. Perou, G. Karaca et al., “Identification of a basal-like subtype of breast ductal carcinoma in situ,” Human Pathology, vol. 38, no. 2, pp. 197–204, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. P. Meijnen, J. L. Peterse, N. Antonini, E. J. T. Rutgers, and M. J. van de Vijver, “Immunohistochemical categorisation of ductal carcinoma in situ of the breast,” British Journal of Cancer, vol. 98, no. 1, pp. 137–142, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. S. Gokhale, D. Rosen, N. Sneige et al., “Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma,” Applied Immunohistochemistry and Molecular Morphology, vol. 15, no. 4, pp. 451–455, 2007. View at Publisher · View at Google Scholar · View at PubMed
  15. D. Faratian, C. Kay, T. Robson et al., “Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM trial experience,” Histopathology, vol. 55, no. 5, pp. 587–593, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. K. L. Bolton, M. Garcia-Closas, R. M. Pfeiffer et al., “Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 4, pp. 992–999, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. D. C. Allred, Y. Wu, S. Mao et al., “Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution,” Clinical Cancer Research, vol. 14, no. 2, pp. 370–378, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. A. Nassar, A. Radhakrishnan, I. A. Cabrero, G. A. Cotsonis, and C. Cohen, “Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study,” Applied Immunohistochemistry and Molecular Morphology, vol. 18, no. 5, pp. 433–441, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. T. M. A. Abdel-Fatah, D. G. Powe, Z. Hodi, J. S. Reis-Filho, A. H. S. Lee, and I. O. Ellis, “Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family,” American Journal of Surgical Pathology, vol. 32, no. 4, pp. 513–523, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. V. L. Ernster, R. Ballard-Barbash, W. E. Barlow et al., “Detection of ductal carcinoma in situ in women undergoing screening mammography,” Journal of the National Cancer Institute, vol. 94, no. 20, pp. 1546–1554, 2002. View at Google Scholar · View at Scopus
  21. M. E. Sanders, P. A. Schuyler, W. D. Dupont, and D. L. Page, “The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up,” Cancer, vol. 103, no. 12, pp. 2481–2484, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. L. A. Carey, C. M. Perou, C. A. Livasy et al., “Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study,” Journal of the American Medical Association, vol. 295, no. 21, pp. 2492–2502, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. R. Bhargava and D. J. Dabbs, “Luminal B breast tumors are not HER2 positive,” Breast Cancer Research, vol. 10, no. 5, pp. 404–405, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. E. Liu, A. Thor, M. He, M. Barcos, B. M. Ljung, and C. Benz, “The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast,” Oncogene, vol. 7, no. 5, pp. 1027–1032, 1992. View at Google Scholar · View at Scopus
  25. A. Hoque, N. Sneige, A. A. Sahin et al., “HER-2/neu gene amplification in ductal carcinoma in situ of the breast,” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 6, pp. 587–590, 2002. View at Google Scholar · View at Scopus
  26. R. E. Roses, E. C. Paulson, A. Sharma et al., “HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 5, pp. 1385–1389, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. X. F. Wen, G. Yang, W. Mao et al., “HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy,” Oncogene, vol. 25, no. 52, pp. 6986–6996, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. A. Evans, S. Pinder, R. Wilson et al., “Ductal carcinoma in situ of the breast: correlation between mammographic and pathologic findings,” American Journal of Roentgenology, vol. 162, no. 6, pp. 1307–1311, 1994. View at Google Scholar · View at Scopus
  29. E. Rakha and J. S. Reis-Filho, “Basal-like breast carcinoma: from expression profiling to routine practice,” Archives of Pathology and Laboratory Medicine, vol. 133, no. 6, pp. 860–868, 2009. View at Google Scholar · View at Scopus
  30. D. J. Dabbs, M. Chivukula, G. Carter, and R. Bhargava, “Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile,” Modern Pathology, vol. 19, no. 11, pp. 1506–1511, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. A. J. M. Connor, S. E. Pinder, C. W. Elston et al., “Intratumoural heterogeneity of proliferation in invasive breast carcinoma evaluated with MIB1 antibody,” The Breast, vol. 6, no. 4, pp. 171–176, 1997. View at Publisher · View at Google Scholar
  32. X. J. Ma, R. Salunga, J. T. Tuggle et al., “Gene expression profiles of human breast cancer progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 5974–5979, 2003. View at Publisher · View at Google Scholar · View at PubMed
  33. A. Orimo, P. B. Gupta, D. C. Sgroi et al., “Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion,” Cell, vol. 121, no. 3, pp. 335–348, 2005. View at Publisher · View at Google Scholar · View at PubMed
  34. M. Allinen, R. Beroukhim, L. Cai et al., “Molecular characterization of the tumor microenvironment in breast cancer,” Cancer Cell, vol. 6, no. 1, pp. 17–32, 2004. View at Publisher · View at Google Scholar · View at PubMed
  35. M. C. Schorr, J. L. Pedrini, R. F. Savaris, and C. G. Zettler, “Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?” Applied Immunohistochemistry and Molecular Morphology, vol. 18, no. 1, pp. 51–54, 2010. View at Publisher · View at Google Scholar · View at PubMed